Jazz Pharmaceuticals JAZZ Non-cash interest expense
Non-cash interest expense at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:NoncashInterestExpense.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's non-cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's non-cash interest expense?
- Jazz Pharmaceuticals (JAZZ) reported non-cash interest expense of $4.7M in Q1 2026.
- How has Jazz Pharmaceuticals's non-cash interest expense changed year-over-year?
- Jazz Pharmaceuticals's non-cash interest expense decreased by 72.5% year-over-year, from $17.1M to $4.7M.
- What is the long-term trend for Jazz Pharmaceuticals's non-cash interest expense?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's non-cash interest expense has grown at a -23.0% compound annual growth rate (CAGR), from $92.66M to $32.54M.
- What does non-cash interest expense mean?
- Interest-related accounting expenses that do not involve actual cash payments.
- How do you interpret non-cash interest expense?
- High non-cash interest may indicate complex debt structures or the use of convertible instruments.
- How does non-cash interest expense compare across companies?
- Common for companies with significant long-term debt or complex financing arrangements.